Biden administration guidance prioritizes race in administering COVID drugs

Guidance issued under the Biden administration states certain individuals may be considered “high risk” and more quickly qualify for monoclonal antibodies and oral antivirals used to treat COVID-19 based on their “race or ethnicity.”